Genomic profiling of immature hematopoietic cells to obtain insights into imatinib resistance

ABSTRACT: Chronic myeloid leukemia (CML) epitomizes successful targeted therapy, with 86% of patients in the chronic phase treated with tyrosine kinase inhibitors (TKIs) attaining remission. However, resistance to TKIs occurs during treatment, and patients with resistance to TKIs progress to the acute phase called Blast Crisis (BC), wherein the survival is restricted to 7-11 months. About 80 % of patients in BC are unresponsive to TKIs. This issue can be addressed by identifying a molecular signature which can predict resistance in CML-CP prior to treatment as well as by delineating the molecular mechanism underlying resistance. Herein, we report genomic analysis of CML patients and imatinib-resistant K562 cell line to achieve the same. Thirteen CML patients (sensitive and resistant to TKIs) and 2 B

ORGANISM(S): Homo sapiens

SUBMITTER: Dr Rukmini Govekar 

PROVIDER: E-MTAB-11899 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress